Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Carcinoma
Both
Carcinoma
Trial Information
Open, Multicenter Observational Study of Paclitaxel Utilized in Mono- or Combination Therapy for the Treatment of Breast Cancer, Non-small Cell Lung Cancer and Ovarial Cancer.
Inclusion Criteria:
- Indication for Paclitaxel according to the SmPC and treating physician
Exclusion Criteria:
- according to the Paclitaxel SmPC
Type of Study:
Observational
Study Design:
Time Perspective: Prospective
Outcome Measure:
the quantity of Paclitaxel onkovis needed pro treatment cycle
Outcome Description:
Determine the quantity of Paclitaxel onkovis needed pro treatment cycle
Outcome Time Frame:
the time the participants will be followed depends on the number of treatment cycles; that means the time frame may extend up to 24 weeks (8 cycles).
Safety Issue:
No
Authority:
Germany: Federal Institute for Drugs and Medical Devices
Study ID:
ONKOPAC 01
NCT ID:
NCT01668108
Start Date:
August 2012
Completion Date:
July 2014
Related Keywords:
- Carcinoma
- carcinoma
- breast cancer
- non-small cell lung cancer
- ovarial cancer
- ambulant chemotherapy
- treatment cycles
- Paclitaxel
- Paclitaxel onkovis
- Quantity of Paclitaxel
- Packaging Sizes
- Breast Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
Name | Location |
|---|
